(function(doc, html, url) { var widget = doc.createElement("div"); widget.innerHTML = html; var script = doc.currentScript; // e = a.currentScript; if (!script) { var scripts = doc.scripts; for (var i = 0; i < scripts.length; ++i) { script = scripts[i]; if (script.src && script.src.indexOf(url) != -1) break; } } script.parentElement.replaceChild(widget, script); }(document, '

Ninjin’yoeito for Anorexia, Apathy, and Cognitive Dysfunction in Frail Alzheimer’s Disease

What is it about?

The apathy and frailty are risk factors in Alzheimer's disease (AD) progresses. However, there is currently no effective drug for treating both anorexia and apathy in AD. Here, we conducted an open-label pilot study to determine whether ninjin’yoeito (NYT, TJ-108), a multicomponent drug, is effective for improving anorexia and apathy in patients with AD, and consequently their cognitive function. After treatment, significant improvements were observed in the scores for “anorexia” and “apathy” by NPI, meal ingestion amount and cognitive dysfunction by MMSE.

Why is it important?

We propose that NYT, a multicomponent drug with several effects including dopamine modulation, is a new-type dementia therapeutic agent with low risk of adverse reactions that can improve simultaneously anorexia/apathy, as well as cognitive dysfunction in frail AD patients.

Read more on Kudos…
The following have contributed to this page:
Makoto Ohsawa
' ,"url"));